Aldeyra eyes the future
A pivotal hit in allergic conjunctivitis could also bode well for upcoming readouts in the bigger indication of dry eye disease.
Bausch boosted ahead of eye spin-off
NOV03 posts a pivotal win but the late-stage dry eye pipeline is crowded.
Proqr hopes to usherin a new ophthalmic therapy
The group’s antisense project is the only game in town for Usher syndrome, but its latest trial is not a slam-dunk.
Frequency refuses to hear the death knell
The company placed part of the blame for its mid-stage hearing loss failure on subjects exaggerating their level of hearing loss.
Cholesterol fears rock Immunovant
Immunovant and other FcRn-players must hope that a potential safety signal turns out to be indication rather than class specific.
Roche eyes an uncertain market for faricimab
Usually a double pivotal trial hit would be cause for celebration, but it might not be enough for Roche.
